As per MRFR analysis, the India Biosimilar Contract Manufacturing Market Size was estimated at 260.05 (USD Million) in 2023. The India Biosimilar Contract Manufacturing Market Industry is expected to grow from 309.2(USD Million) in 2024 to 2,300.1 (USD Million) by 2035. The India Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 20.013% during the forecast period (2025 - 2035).
A number of main market drivers in the India Biosimilar Contract Manufacturing Market are driving significant growth. A primary factor is the growing prevalence of chronic diseases and the corresponding demand for affordable treatment options. To further enhance the market's potential, the Indian government is actively promoting biosimilars through policies that encourage research and development.
Regulatory bodies, such as the Central Drugs Standard Control Organization, are simplifying the approval process for biosimilars, thereby facilitating the entry of manufacturers into the market and raising competition. This market offers a plethora of opportunities that should be evaluated. The enormous availability of a skilled workforce and the lower production costs render Indian manufacturers well-positioned to capitalize on these opportunities. Major pharmaceutical companies are transitioning to delegating biosimilar production to contract manufacturers, which is fostering a favorable environment for Indian firms.
Furthermore, partnerships and collaborations with global biotechnology companies can allow local actors to improve their technological capabilities and product offerings. There has been a notable trend in India in recent years of increasing investment in biopharmaceutical infrastructure and technology.
The nation is experiencing an increase in the number of facilities that are specifically designed for the production and development of biosimilars, most of which adhere to international standards. Additionally, Indian companies are in pursuit of a greater market share, which is reflected in the growing trend of innovation in biotherapeutic development. Such trends suggest that the biosimilar contract manufacturing sector is both robust and evolving, establishing India as a global centre for the production of these essential therapeutics.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer in India is a significant driver for the India Biosimilar Contract Manufacturing Market. According to the National Health Profile 2021, India has seen a staggering increase in diabetes prevalence, with over 77 million individuals currently affected.
With the World Health Organization estimating that by 2030, diabetes could become the seventh leading cause of death globally, the demand for affordable treatment options such as biosimilars is projected to soar.Established organizations like Biocon and Dr. Reddy's Laboratories, which focus heavily on biosimilars, are expected to meet this increasing demand.
The government’s push in the Ayushman Bharat initiative aims to provide healthcare services to around 500 million individuals, which further bolsters the need for effective treatment alternatives. As chronic diseases continue to rise in India, the biosimilar contract manufacturing sector is primed for substantial growth.
The Government of India has implemented various policies to promote the development and manufacturing of biosimilars. Initiatives such as the Biotechnology Industry Research Assistance Council aim to encourage the growth of biopharmaceutical innovation, which paves the way for the India Biosimilar Contract Manufacturing Market Industry.
In addition, the recent introduction of the 'Pharma Vision 2020' policy outlines competency in the biopharmaceutical sector to enhance access to high-quality medicines.This supportive government framework has led to an increase in Research and Development (R&D) activities, allowing domestic firms to compete globally.
With the Indian government's aim to increase the biopharmaceutical market size to USD 100 billion by 2025, the encouragement for contract manufacturing in this area is crucial, stimulating future market growth.
The escalating healthcare costs in India present a significant driver for the biosimilar contract manufacturing market. With India being home to over 1.3 billion people, the affordability of medications has become critical. The National Pharmaceutical Pricing Authority has put in place price control measures, ensuring that essential drugs remain affordable.
Reports suggest that biosimilars can be up to 30% less expensive than their reference biologics, making them an attractive option for healthcare providers and patients alike.Companies like Intas Pharmaceuticals and Mylan are strategically entering the biosimilar market to cater to this rising demand for economically viable treatment options.
As the price-sensitive Indian population seeks effective yet affordable treatments, the demand for biosimilars is set to increase, significantly fuelling market growth.
Technological advancements in biologics manufacturing are redefining the capabilities of the India Biosimilar Contract Manufacturing Market Industry. The adoption of cutting-edge techniques such as continuous manufacturing and advanced bioprocessing methods streamlines the production of biosimilars, enhancing yield and reducing costs.
Research by the Department of Biotechnology highlights that innovative bioreactor technology and automation can boost productivity by 20-30%.Notable firms like Parexel and Lonza are at the forefront of implementing these advanced technologies in India, significantly impacting operational efficiency.
Enhanced manufacturing capabilities will enable Indian companies to meet the growing demand for biosimilars, solidifying their position in the global market and promoting extensive growth in this sector.
The India Biosimilar Contract Manufacturing Market has been experiencing significant growth, with the Product segment playing a pivotal role in shaping its dynamics. Particularly noteworthy within this segment are Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, both of which hold essential positions in the production of biosimilars.
Recombinant Non-glycosylated Proteins are vital due to their simpler structures, leading to lower production costs and quicker development timelines. This sub-segment dominates the industry by catering to various applications within therapeutics, enhancing drug efficacy, and ensuring patient safety.
On the other hand, Recombinant Glycosylated Proteins account for a crucial part of the market because they tend to closely mimic the natural proteins found in human systems. This similarity often results in enhanced therapeutic effects, increased stability, and improved pharmacokinetics, thus driving demand across multiple therapeutic areas, including oncology and autoimmune diseases.
The landscape for both these categories is driven by advancements in biotechnology, evolving regulatory frameworks, and a growing need for affordable healthcare solutions in India.The government’s initiatives to promote biotechnology and reduce healthcare costs support the growth trajectory, further bolstering the position of these products within the India Biosimilar Contract Manufacturing Market.
With increasing investments in Research and Development, coupled with advancements in technology, the competitive environment for these products is expected to strengthen, paving the way for innovative solutions to emerge. Additionally, as the healthcare sector in India continues to expand, the demand for biosimilars is expected to rise steadily, highlighting the significant opportunities available in both Recombinant Non-glycosylated and Glycosylated Protein spaces.
The growth drivers for this market segment include the rising prevalence of chronic diseases, increased healthcare expenditure, and a growing acceptance of biosimilar products among healthcare professionals and patients alike. Despite facing challenges such as stringent regulatory requirements and the need for extensive clinical trials, the overall outlook for the Product segment remains positive, with prospects for continuous evolution and expansion in the coming years.
The integration of digital technologies and automation in production processes is further expected to enhance efficiency and reduce operational costs, positioning the India Biosimilar Contract Manufacturing Market as a key player in the global biosimilars landscape.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The Production Technology segment of the India Biosimilar Contract Manufacturing Market encompasses critical advancements in the development and manufacturing processes of biosimilars. This segment is categorized into two primary areas Mammalian and Non-Mammalian technologies, each playing a vital role in the efficiency and effectiveness of biosimilar production.
Mammalian systems are often preferred for their ability to perform complex post-translational modifications, making them suitable for producing more sophisticated therapeutic proteins.This capability is essential for ensuring that biosimilars mimic the original biologics closely, which is crucial for therapeutic efficacy and regulatory approval.
In contrast, Non-Mammalian systems, such as yeast and bacteria, offer advantages in cost efficiency and faster production times, making them significant in meeting the increasing demand for biosimilars. The diversity in production technologies allows India to cater to various therapeutic areas while adapting to global standards. Given the rise in chronic diseases and a growing patient population in India, the significance of these production technologies cannot be overstated, as they align with the strategic goals of enhancing healthcare access and affordability in the region.The India Biosimilar Contract Manufacturing Market is witnessing a shift towards innovation and technological advancements, reflecting the nation's commitment to becoming a global leader in biomanufacturing.
The Application segment of the India Biosimilar Contract Manufacturing Market highlights a crucial area of growth and expansion in the healthcare sector, focusing on various therapeutic areas such as Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, and Rheumatoid Arthritis. With the rising prevalence of cancer and chronic diseases in India, the demand for effective biosimilar solutions is becoming increasingly significant.
Oncology is a major focal point due to the growing cancer population, driving innovations in treatment methodologies.
Blood Disorders, including conditions like anemia, are also gaining traction, necessitating cost-effective alternatives to branded biologics. In addition, the therapeutic area addressing Growth Hormonal Deficiency showcases the importance of personalized medicine in improving patient outcomes.
Chronic and Autoimmune Disorders are increasingly impacting the Indian populace, placing immense pressure on healthcare systems to provide accessible treatment options, thus underscoring the importance of biosimilars. As healthcare strategies evolve, the sub-segment concerning Rheumatoid Arthritis holds a vital role in addressing chronic inflammation and joint disease, providing substantial relief to affected individuals.
The diversity within this segment reflects the broader trends affecting the India Biosimilar Contract Manufacturing Market, where increased access, cost-efficiency, and efficacy of treatments represent key growth drivers in the industry.
The India Biosimilar Contract Manufacturing Market has emerged as a critical segment within the pharmaceutical industry, characterized by rapid growth and increased competition. The rising demand for cost-effective alternatives to biological drugs and the increasing focus on precision medicine primarily drive this market.
With a plethora of companies vying for market share, the landscape becomes defined by strategic collaborations, technological advancements, and significant investments aimed at enhancing manufacturing capabilities. The competition is further intensified by the regulatory environment that governs the approval and commercialization of biosimilars, necessitating manufacturers to adopt agile and compliant processes.
Companies are keenly observing market trends to differentiate their offerings and effectively cater to the diverse needs of healthcare providers and patients.Sun Pharmaceutical Industries has established a prominent foothold in the India Biosimilar Contract Manufacturing Market, leveraging its extensive experience and robust R&D capabilities.
The company is recognized for its strong product portfolio, which includes a variety of biosimilar options targeted at chronic diseases such as cancer and autoimmune disorders. Sun Pharmaceutical's significant investment in state-of-the-art manufacturing facilities enables it to maintain high-quality standards while ensuring compliance with stringent regulatory guidelines.
The company’s strategic alliances and partnerships further bolster its market presence, fostering innovation and enhancing its competitive edge. Additionally, Sun Pharmaceutical's commitment to cost-effective solutions allows it to cater to a broader patient base, thereby contributing to its growth and stability within this segment.
Biocon has emerged as a key player in the India Biosimilar Contract Manufacturing Market, distinguished by its comprehensive range of biopharmaceutical products and services. The company offers biosimilars focused on diabetes, oncology, and autoimmune diseases, gaining a solid reputation for its commitment to quality and efficacy.
Biocon has made significant strides in expanding its manufacturing capabilities through modern facilities that meet international standards, positioning itself as an attractive partner for contract manufacturing services. The company has also engaged in strategic collaborations and mergers that enhance its production capacity and market reach, further solidifying its position in the biosimilars sector. Biocon's ongoing efforts in research and development, coupled with its strong market presence, enable it to remain competitive within the growing landscape of biosimilars in India.
In the India Biosimilar Contract Manufacturing Market, significant recent developments include the ongoing expansion efforts of leading firms such as Sun Pharmaceutical Industries and Biocon. Sun Pharma has been enhancing its production capabilities to meet rising global biosimilar demands.
In June 2023, Biocon announced its strategic partnership with Siro Clinpharm, aimed at bolstering its contract research and manufacturing services, reflecting a growth trend in collaborative ventures. Intas Pharmaceuticals continues to invest in Research and Development for biosimilars, pushing for innovative drug solutions amidst increasing competition.
The market has also seen notable mergers and acquisitions for instance, Hetero Labs acquired a minority stake in a European biosimilar company in July 2023, strengthening its international presence. Companies like Zydus Cadila and Dr Reddy's Laboratories are diversifying their product portfolios, enhancing their manufacturing capabilities to capture a larger market share.
The overall market valuation for these companies shows a positive growth trajectory, influenced by rising demand for affordable biologics in India and globally. The Indian government has also been supportive of biosimilar development, fostering an environment conducive to innovation within the sector over the past 2-3 years.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 260.05(USD Million) |
| MARKET SIZE 2024 | 309.2(USD Million) |
| MARKET SIZE 2035 | 2300.1(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.013% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Sun Pharmaceutical Industries, Biocon, Intas Pharmaceuticals, Mabxience, Cipla, Wockhardt, Siro Clinpharm, Hetero Labs, Novo Nordisk, Zydus Cadila, Alvogen, Dr Reddy's Laboratories, Sagent Pharmaceuticals, Mynvax, Aarti Industries |
| SEGMENTS COVERED | Product, Production Technology, Application |
| KEY MARKET OPPORTUNITIES | Increasing global demand for biosimilars, Expanding manufacturing capacities and facilities, Cost-effective production processes, Strategic partnerships with biopharma companies, Regulatory incentives for biosimilar products |
| KEY MARKET DYNAMICS | Regulatory support, Cost-effective production, Rising chronic diseases, Increasing acceptance of biosimilars, Collaboration with biotech firms |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The market is expected to be valued at 309.2 million USD in 2024.
By 2035, the market is projected to reach a value of 2300.1 million USD.
The expected CAGR for the market during this forecast period is 20.013%.
The Recombinant Glycosylated Proteins segment is anticipated to grow from 186.0 million USD in 2024 to 1387.1 million USD by 2035.
The market value for Recombinant Non-glycosylated Proteins is expected to reach 913.0 million USD in 2035.
Major players in the market include Sun Pharmaceutical Industries, Biocon, Intas Pharmaceuticals, and Cipla.
Key growth drivers include increasing demand for cost-effective therapeutics and advancements in biotechnology.
Emerging trends include collaboration among biopharma companies and growing investments in biosimilar development.
The landscape is competitive with several companies vying for market share through innovation and strategic partnerships.
Challenges include regulatory hurdles and the need for extensive clinical trials to establish efficacy and safety.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
